A Study of Eltrekibart (LY3041658) in Healthy Participants

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history and physical examination * Have a minimum body weight of 45 kilograms (kg). * Have a body mass index (BMI) within the range of 18.5 to 28.5 kilograms per square meter (kg/m²), inclusive Exclusion Criteria: * Have multiple severe allergies to prescription or nonprescription drugs * Are immunocompromised * Have had any of the following types of infection within 3 months prior to the screening visit: * Serious, that is, requiring hospitalization, or intravenous or equivalent oral antibiotic treatment * Opportunistic infections Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over * Chronic, that is, duration of symptoms, signs, or treatment of 6 weeks or longer, or * Recurring, including, but not limited to: * herpes simplex, * herpes zoster, * recurring cellulitis, or * chronic osteomyelitis. * Are currently pregnant or are intending to become pregnant or to breastfeed at any time in the study or within 16 weeks after receiving the single dose of study intervention.